PLK1 and cholangiocarcinoma: Therefore, dual-targeting AA-HA-ODA for CAFs and cholangiocarcinoma cells was constructed to deliver a PLK1 inhibitor sequentially to verify the effectiveness of inhibiting CAFs and PLK1 in vivo, which might provide enlightenment for multitarget treatment strategies and guidance for clinical cholangiocarcinoma treatment.